HCA Healthcare financials
$431.63−0.22%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B | $51.53B | $51.34B | $46.68B | $43.61B | $41.49B |
| Gross profit | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B | $51.53B | $51.34B | $46.68B | $43.61B | $41.49B |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | $12.00B | $10.56B | $9.62B | $9.05B | $9.68B | $7.26B | $7.22B | $6.64B | $6.06B | $6.20B |
| Net income | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B | $3.75B | $3.50B | $3.79B | $2.22B | $2.89B |
| Net margin | 9.0% | 8.2% | 8.1% | 9.4% | 11.8% | 7.3% | 6.8% | 8.1% | 5.1% | 7.0% |
| Diluted EPS | $28.33 | $22.00 | $18.97 | $19.15 | $21.16 | $10.93 | $10.07 | $10.66 | $5.95 | $7.30 |
| EBITDA | $15.53B | $13.87B | $12.70B | $12.02B | $12.53B | $9.98B | $9.81B | $8.92B | $8.19B | $8.16B |
| Operating cash flow | $12.64B | $10.51B | $9.43B | $8.52B | $8.96B | $9.23B | $7.60B | $6.76B | $5.43B | $5.65B |
| Free cash flow | $7.69B | $5.64B | $4.69B | $4.13B | $5.38B | $6.40B | $3.44B | $3.19B | $2.41B | $2.89B |
| Diluted shares | 239.5M | 261.8M | 276.4M | 294.7M | 328.8M | 343.6M | 348.2M | 355.3M | 372.2M | 395.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.04B | $1.93B | $935.0M | $908.0M | $1.45B | $1.79B |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $46.49B | $43.03B | $39.59B | $38.08B | $34.58B | $31.00B |
| Total assets | $60.72B | $59.51B | $56.21B | $52.44B | $50.74B | $47.49B |
| Total liabilities | $63.49B | $58.96B | $55.15B | $52.51B | $49.25B | $44.60B |
| Shareholders' equity | -$2.77B | $555.0M | $1.06B | -$73.0M | $1.49B | $2.89B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology